Who is sponsoring NCT01188759?

NCT01188759 is sponsored by Pfizer.

What condition does NCT01188759 study?

NCT01188759 studies Aspergillosis, Invasive Pulmonary Aspergillosis, Neuroaspergillosis.

What drugs are being tested in NCT01188759?

Interventions: Voriconazole, Anidulafungin, Voriconazole.

What is the status of NCT01188759?

NCT01188759 is currently WITHDRAWN.

Last reviewed 2012-05-10 · How we verify

A Prospective, Randomized Trial Comparing The Safety, Tolerability, And Efficacy Of Voriconazole And Anidulafungin In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Invasive Aspergillosis in Pediatric Subjects Aged 2 to 17 Years

NCT01188759 Phase 3 WITHDRAWN

This study aims to compare the safety, tolerability, and efficacy of voriconazole and anidulafungin in combination versus voriconazole alone in pediatric subjects aged 2 to 17 years with invasive aspergillosis.

Details

Lead sponsor	Pfizer
Phase	Phase 3
Status	WITHDRAWN
Start date	2012-05
Completion	2014-08

Conditions

Aspergillosis
Invasive Pulmonary Aspergillosis
Neuroaspergillosis

Interventions

Voriconazole
Anidulafungin
Voriconazole

Primary outcomes

Safety and tolerability of voriconazole and anidulafungin in combination versus voriconazole alone as determined by rates of adverse events — 12 weeks